A28 RESPONSE RATE OF VERY EARLY ONSET INFLAMMATORY BOWEL DISEASE (VEOIBD) PATIENTS TO ANTI-TNF TREATMENT IS HIGHER THAN PREVIOUSLY REPORTED, BUT HIGHER DOSING IS REQUIRED-A LARGE TERTIARY SINGLE CENTER EXPERIENCE

BACKGROUND: Very early onset inflammatory bowel disease (VEOIBD) patients are known to have special disease characteristics. Limited data is available regarding biologic use and long-term outcomes in VEOIBD patients. AIMS: We aimed to assess long-term outcomes and time to progression to biologic tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Eindor, A, Meleady, L, Jacobson, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Poster of Distinction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859247/
http://dx.doi.org/10.1093/jcag/gwab049.027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859247/
http://dx.doi.org/10.1093/jcag/gwab049.027

Ejemplares similares